Aetna Applauds FDA Decision Maintaining Access to Affordable Medication for Pregnant Women at Risk for Premature Deliverie

HARTFORD, Conn.--(BUSINESS WIRE)-- The United States Food and Drug Administration today announced that specialty pharmacies can continue compounding 17P (hydroxyprogesterone caproate) based on a valid prescription for an individually identified patient.

“Today's FDA decision is an outstanding win for women and their at-risk babies who may have lost access to a safe and cost-effective treatment to help prevent preterm birth. Aetna has championed the need to provide 17P at an affordable price so that pregnant women would not face a 100-fold increase in treatment cost. The FDA's decision is well-reasoned and helps keep quality health care more affordable,” said Lonny Reisman, M.D., Aetna chief medical officer.

About Aetna

Aetna (NYSE: AET) is one of the nation’s leading diversified health care benefits companies, serving approximately 35.3 million people with information and resources to help them make better informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, and medical management capabilities and health care management services for Medicaid plans. Our customers include employer groups, individuals, college students, part-time and hourly workers, health plans, governmental units, government-sponsored plans, labor groups and expatriates. For more information, see www.aetna.com. To learn more about Aetna's innovative online tools, visit www.aetnatools.com.



CONTACT:

Aetna
Tammy Arnold, 713-721-7891
[email protected]

KEYWORDS:   United States  North America  Connecticut

INDUSTRY KEYWORDS:   Women  Health  Pharmaceutical  Professional Services  Insurance  FDA  Consumer  General Health  Managed Care

MEDIA:

Logo
 Logo

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.